ERBB2 and neoplasm: [212Pb]Pb-TCMC-panitumumab demonstrated superior therapeutic effects in immunocompromised LS-174T tumor xenografts compared to [212Pb]Pb-TCMC-cetuximab or the HER2 targeting [212Pb]Pb-TCMC-trastuzumab.